Piper Sandler Reiterates Overweight Rating on Amphastar Pharmaceuticals (AMPH)

May 23, 2024 8:45 AM EDT Send to a Friend
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $71.00 price target on Amphastar Pharmaceuticals (NASDAQ: AMPH).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login